LAUSR

The present study examined the wheat protein gliadin‐induced oxidative and nitrosative stress and its downstream responses in human intestinal HCT‐116 and HT‐29 cells. The beneficial role of dietary phytochemical curcumin and role of multifunctional enzyme Apurinic/aprymidinic endonuclease 1 (APE1) a major player involved in the base excision repair (BER)‐pathway in gliadin intolerant intestinal HCT‐116 and HT‐29 cell lines were evaluated as an in vitro model study. The cultured cells were exposed to gliadin protein, H2O2, and curcumin followed by the assessment of oxidative stress and the consequences were measured using spectrophotometric, PCR, flow cytometer, Western blotting, confocal microscopy, and other methods. Results demonstrate that a 3 h pretreatment of curcumin, followed by the treatment of gliadin protein for 24 h time period protected both the HCT‐116 and HT‐29 cells via: (i) decreasing the ROS/RNS, restoring the mitochondrial transmembrane potential; (ii) re‐establishing the cellular antioxidant defense system (superoxide dismutase, catalase, and GSH); (iii) enhancing the functions of APE1 viz. endonuclease activity and redox activation of transcription factor Nrf‐2, the later binds with the antioxidant response elements (ARE) and activates downstream targets involved in cell survival. The cross‐talk between APE1 and Nrf‐2 was also established using immunofluorescence imaging and co‐immunoprecipitation assays. In conclusion, gliadin protein induces oxidative/nitrosative stress, mitochondrial dysfunction and it damages cellular biomolecules in the intestinal cells. Hence it can be attributed to the tissue damage and disease pathogenesis in wheat intolerance‐associated intestinal diseases. The gliadin‐induced stress and its consequences are significantly reduced by the pretreatment of curcumin via BER‐pathway and ARE‐pathway; which is evident through the interaction between these two essential proteins. Hence suggesting for the intervention of curcumin and other natural dietary phytochemicals‐based disease management and treatment of gliadin intolerance associated intestinal diseases like celiac disease.